Artia Global Partners LP Takes $4.16 Million Position in Palisade Bio, Inc. $PALI

Artia Global Partners LP purchased a new stake in shares of Palisade Bio, Inc. (NASDAQ:PALI - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,992,367 shares of the company's stock, valued at approximately $4,164,000. Palisade Bio makes up about 0.8% of Artia Global Partners LP's portfolio, making the stock its 28th largest holding. Artia Global Partners LP owned approximately 1.14% of Palisade Bio as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. Cetera Investment Advisers bought a new stake in shares of Palisade Bio in the 4th quarter worth $25,000. Schonfeld Strategic Advisors LLC bought a new position in shares of Palisade Bio during the fourth quarter valued at $26,000. Virtu Financial LLC purchased a new stake in shares of Palisade Bio during the fourth quarter valued at $28,000. Legal & General Group Plc purchased a new stake in shares of Palisade Bio during the second quarter valued at $30,000. Finally, CTC Alternative Strategies Ltd. bought a new stake in Palisade Bio in the 1st quarter worth about $31,000. 11.79% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on PALI. Oppenheimer began coverage on shares of Palisade Bio in a research note on Thursday, July 23rd. They issued an "outperform" rating and a $8.00 price target for the company. Weiss Ratings cut shares of Palisade Bio from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, July 14th. Wall Street Zen raised shares of Palisade Bio from a "sell" rating to a "hold" rating in a research report on Saturday, July 25th. HC Wainwright reiterated a "buy" rating and set a $2.00 target price on shares of Palisade Bio in a research note on Tuesday, June 30th. Finally, LADENBURG THALM/SH SH raised Palisade Bio to a "strong-buy" rating in a report on Thursday, June 25th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $9.00.

Palisade Bio Stock Up 2.9%

Shares of NASDAQ:PALI opened at $2.13 on Thursday. The stock has a market capitalization of $371.20 million, a PE ratio of -4.44 and a beta of 1.52. The firm's 50 day moving average price is $2.01 and its 200-day moving average price is $1.94. Palisade Bio, Inc. has a twelve month low of $0.53 and a twelve month high of $2.86.

Palisade Bio (NASDAQ:PALI - Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05). The business had revenue of $0.50 million for the quarter, compared to the consensus estimate of $0.50 million. Analysts expect that Palisade Bio, Inc. will post -0.23 earnings per share for the current fiscal year.

Insider Transactions at Palisade Bio

In related news, CEO John David Finley sold 146,798 shares of the firm's stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $2.07, for a total value of $303,871.86. Following the transaction, the chief executive officer directly owned 217,555 shares of the company's stock, valued at approximately $450,338.85. This trade represents a 40.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Robert Jr. Baltera bought 25,000 shares of the stock in a transaction that occurred on Thursday, July 9th. The shares were bought at an average price of $1.96 per share, for a total transaction of $49,000.00. Following the completion of the transaction, the director directly owned 461,904 shares of the company's stock, valued at $905,331.84. This represents a 5.72% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 125,000 shares of company stock worth $250,100 in the last three months. Corporate insiders own 0.07% of the company's stock.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.

Want to see what other hedge funds are holding PALI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Palisade Bio, Inc. (NASDAQ:PALI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source